Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance [1]

Annals of Oncology

Volumn 15, Issue 1, 2004, Pages 173-

  Kurata, T ^a   Tamura, K ^a   Kaneda, H ^a   Nogami, T ^a   Uejima, H ^a   Asai, G ^a   Nakagawa, K ^a   Fukuoka, M ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; IRINOTECAN; NEDAPLATIN; PACLITAXEL;

AGED; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CASE REPORT; CLINICAL TRIAL; HUMAN; LETTER; LUNG ADENOCARCINOMA; LUNG METASTASIS; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; RETREATMENT; TREATMENT PLANNING;

EID: 0942287932     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh006     Document Type: Letter

References (5)

1. Negoro S, Nakagawa K, Fukuoka M et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumors. Proc Am Soc Clin Oncol 2001; 20: 324a.
2. Kameyama Y, Okazaki N, Nakagawa M et al. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 1990; 52: 15-24.
3. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT- 11) is active in CPT- 11 -refractory colorectal cancer (CRC) that express epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 20: 3a.
4. Giaccone G, Johnson DH, Manegold C et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002; 13 (Suppl 5): 2.
5. Johnson DH, Herbst R, Giaccone G et al. ZD 1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002; 13 (Suppl 5): 127.